Clinical trials: Bowel Cancer
Colorectal Cancer, Advanced Adenocarcinoma
A Multicenter Clinical Trial of Stool-based DNA Testing for Early Detection of Colon Cancer in China
According to data from Global Cancer Statistics 2018, colorectal cancer (CRC) ranks second in incidence and fifth in mortality among all cancers in China.
- Conditions
- Colorectal Cancer, Advanced Adenocarcinoma, Hyperplastic Polyp, Colorectal Neoplasms
- Trial name
- NCT04722055
- Testing
- Multigene Methylation Detection Kit
- Where
- China
- Volunteers
- 1,273 people, healthy volunteers welcome
- Sponsor
- Creative Biosciences (Guangzhou) Co., Ltd.
Colon Cancer, Gastrointestinal Cancer
Seal-G / Seal-G MIST Study
A prospective, multi-center, open label, study to evaluate safety and performance of Seal-G and Seal-G MIST in reinforcing colonic anastomosis, in subjects undergoing Colon Resection surgery
- Trial name
- NCT04532515
- Testing
- Seal-G Surgical Sealant, Seal-G MIST System
- Where
- 2 sites in Israel
- Volunteers
- 160 people
- Sponsor
- Advanced Medical Solutions Ltd.
Lynch Syndrome
Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome.
The purpose of this study is to assess if artificial intelligence aid colonoscopy colonoscopy is superior to conventional colonoscopy for the detection of adenomas during surveillance colonoscopy in patients with Lynch syndrome.
- Trial name
- Timely (NCT04909671)
- Testing
- Gi Genius, Medtronic, White light standart colonoscopy
- Where
- 2 sites in Spain
- Volunteers
- 404 people
- Sponsor
- Hospital Clinic of Barcelona
Rectal Cancer, Low Anterior Resection Syndrome
Autologous Fecal Microbiota Transplantation for Anal Function Recovery After Ileostomy Reversal in Rectal Cancer
This prospective, single-center, single-arm, open-label clinical study aims to evaluate whether autologous fecal microbiota transplantation can improve bowel and anal function after ileostomy reversal in patients with rectal…
- Conditions
- Rectal Cancer, Low Anterior Resection Syndrome, Fecal Incontinence, Diversion Colitis
- Trial name
- NCT07711509
- Testing
- Autologous Fecal Microbiota Transplantation
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Peking University People's Hospital
Metastatic Colorectal Cancer
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
To determine if sorafenib when added to chemotherapy will slow disease progression more than chemotherapy alone in patients previously untreated for metastatic colorectal cancer.
- Trial name
- NCT00865709
- Testing
- Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
- Where
- 116 sites in United States, Belgium and 8 more
- Volunteers
- 198 people
- Sponsor
- Bayer
Rectal Neoplasms
Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy
The purpose of this study is to evaluate the efficacy of adjuvant chemotherapy in patients with clinical stage III rectal cancer who received neoadjuvant chemoradiotherapy on the basis of postoperative pathological stage.
- Trial name
- NCT03415763
- Testing
- Capecitabine, mFOLFOX6 or CAPOX
- Where
- China
- Volunteers
- 764 people
- Sponsor
- LI XIN-XIANG
Colorectal Carcinoma
Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma
The purpose of this study is to evaluate how tumors in patients with colorectal carcinoma respond to treatment with VELCADE alone versus VELCADE given with irinotecan, and also to see what effects (good and bad) it has on you and…
- Trial name
- NCT00051987
- Testing
- VELCADE TM (bortezomib) for Injection, or PS-341
- Where
- 22 sites in United States
- Volunteers
- 175 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
This study is to evaluate the safety and tolerability of of LT-010391 as monotherapy in participants with KRAS G12D mutant advanced solid tumors
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT07624214
- Testing
- LT-010391
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Anal Cancer
Individual Following in Anal Cancer With PET/CT
Anal canal cancer is a relatively rare disease, representing 1.2% of digestive cancers and 6% of anorectal cancers. Incidence is less than 1/100 000 of the general population.
- Trial name
- IFACT (NCT02697084)
- Testing
- anal cancer
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Centre Antoine Lacassagne
Advanced Malignant Solid Neoplasm, RAS Mutation
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed…
- Conditions
- Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer
- Trial name
- NCT04678648
- Testing
- RSC-1255 Dose Escalation, RSC-1255 Dose Expansion
- Where
- 3 sites in United States
- Volunteers
- 134 people
- Sponsor
- RasCal Therapeutics, Inc.
Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma
Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer
*As of June 2026- Phase I has been completed and we are now in Phase II. This phase I/II trial studies the side effects and how well fluorescence image guided surgery followed by intraoperative photodynamic therapy for improving…
- Conditions
- Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer
- Trial name
- NCT06307548
- Testing
- Aminolevulinic Acid, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Colorectal Cancer
Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer
Since its introduction, 5-fluorouracil (5-FU) has been the cornerstone of treatment for metastatic colorectal cancer (mCRC). Meanwhile the oral 5FU pro-drug Capecitabine (Xeloda®) proved equivalence to 5-FU and is a well…
- Trial name
- PASSION (NCT02119026)
- Testing
- Capecitabine, Bevacizumab, Oxaliplatin
- Where
- Austria
- Volunteers
- 120 people
- Sponsor
- Prof. Dr. Werner Scheithauer
Breast Neoplasms, Ovarian Neoplasms
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
The purpose of this study is to better understand the genetic causes of cancer and the inherited tendency to develop cancer. To accomplish this, blood specimens and/or saliva samples and/or tumor and normal tissue blocks from…
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Colonic Neoplasms, Prostatic Neoplasms
- Trial name
- NCT00579163
- Where
- United States
- Volunteers
- 992 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rectal Carcinoma
IMRT-SIB and Capecitabine in Preoperative Rectal Cancer Treatment
RATIONALE: Using small radiation beamlets of different intensity, IMRT (intensity modulated radiation therapy) allows shaping the dose around planning target volume with better sparing of normal tissue comparing to 3D conformal…
- Trial name
- BISER (NCT02268006)
- Testing
- IMRT-SIB, Capecitabine, Surgery
- Where
- Slovenia
- Volunteers
- 50 people
- Sponsor
- Institute of Oncology Ljubljana
Advanced Solid Tumors
Study of Intermittent OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the maximum tolerated dose (MTD) of 3 intermittent OSI-906 dosing schedules.
- Trial name
- NCT00514306
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Astellas Pharma Inc
Colon Cancer, Colon Adenocarcinoma
Survival Outcomes by Tumor-Node Stage and Recurrence Patterns in Colon Cancer After Radical Surgery
Colon cancer is one of the most common cancers worldwide, and even after curative (radical) surgery, some patients develop recurrence or distant metastasis.
- Conditions
- Colon Cancer, Colon Adenocarcinoma, Colon Cancer Stage III, Colon Cancer Stage I
- Trial name
- STARS (NCT07167147)
- Where
- Taiwan
- Volunteers
- 7,259 people
- Sponsor
- Chang Gung Memorial Hospital
Colorectal Cancer, Colorectal Adenoma
Protein Signature Based Screening of Colorectal Adenomas and Cancer
Colorectal cancer is a common cancer, that in general develops over a long time period (approximately 10-15 years) from precancerous polyps. The disease is in many cases asymptomatic.
- Trial name
- NCT07881549
- Where
- Sweden
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Region Skane
Metastatic Colorectal Cancer
"Cancersensor" Metastasis Resection
Observational, non randomized study aimed at measuring the effect of surgical resection of metastasis in the urinary concentrations of physiological modified nucleosides in 45 patients with metastatic colorectal cancer.
- Trial name
- NCT01693848
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Colorectal Cancer
Chemotherapy and Radiation Therapy Before Surgery Followed by Capecitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- PETACC-6 (NCT00766155)
- Testing
- capecitabine, oxaliplatin
- Volunteers
- 1,094 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer
- Trial name
- NCT06625515
- Testing
- ATX-559
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Accent Therapeutics